Welcome to our dedicated page for Immunic SEC filings (Ticker: IMUX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Immunic, Inc. filings document SEC reporting for a Nasdaq-listed biotechnology company developing oral therapies for neurologic disease. Recent Form 8-K reports cover financial results and corporate updates, Nasdaq minimum bid price compliance, stockholder-approved charter amendments, and the reverse stock split affecting its common stock.
Governance disclosures include director and officer appointments, executive compensation arrangements, special-meeting voting results, and definitive proxy materials. The filings also describe registered common stock, capital-structure changes, financing and clinical-program updates, and formal governance and shareholder voting subjects tied to Immunic's late-stage development model.
Aberdeen Group plc and its subsidiary abrdn Inc. report beneficial ownership of 824,393 shares of Immunic, Inc. common stock, representing 6.05 % of the outstanding class. All of these shares are reported with shared, not sole, voting and dispositive power.
The ownership is held by abrdn Inc. on behalf of underlying clients, with Aberdeen Group plc identified as the parent and abrdn Holdings Limited as an intermediate holding company. This amendment updates Immunic’s CUSIP 4525EP200 following a stock split that was effective on April 27, 2026.
Immunic, Inc. reports that on July 14, 2026 it made an updated corporate presentation available on its website, also provided as Exhibit 99.1. The materials are furnished under Regulation FD and are expressly not deemed “filed” or incorporated into other securities law filings unless specifically referenced.
The presentation contains extensive forward-looking statements about Immunic’s strategy, cash runway, clinical development of vidofludimus calcium, potential phase 3 plans in progressive multiple sclerosis, regulatory milestones, Nasdaq listing status, and capital structure. Immunic highlights substantial risks and uncertainties and directs readers to the Risk Factors section of its Form 10-K for the year ended December 31, 2025 and subsequent SEC reports.
IMMUNIC, INC. director Simona Skerjanec received a grant of stock options covering 25,370 shares of common stock. The options have an exercise price of $14.80 per share and expire on July 5, 2036. They vest in monthly increments over one year from the grant date, and following this grant she holds 25,370 options directly.
IMMUNIC, INC. director Richard Alan Rudick received a grant of stock options covering 25,370 shares of common stock as equity compensation. The options have an exercise price of $14.80 per share, vest in monthly increments over one year from the grant date, and expire on July 5, 2036. Following this award, he directly holds 25,370 derivative securities.
IMMUNIC, INC. director Barclay A. Phillips received a grant of stock options that can convert into 25,370 shares of common stock. The options have an exercise price of $14.80 per share and expire on July 5, 2036. They vest in monthly increments over one year from the grant date, and after this award Phillips holds 25,370 stock options directly.
IMMUNIC, INC. director Joerg Neermann received a grant of stock options covering 25,370 shares of common stock. The options have an exercise price of $14.80 per share and expire on July 5, 2036. They vest in monthly increments over one year from the grant date.
IMMUNIC, INC. director Jon Congleton received a grant of stock options covering 25,370 shares of common stock at an exercise price of $14.80 per share. The option vests in monthly installments over one year from the grant date and expires on July 5, 2036. Following this grant, Congleton holds 25,370 options directly, with no accompanying share purchases or sales reported.
Immunic, Inc. reported a board change linked to retirement plans. On June 29, 2026, director Tamar Howson resigned from the Board and its Compensation Committee as she transitions into retirement. The company states her resignation did not result from any disagreement over operations, policies, or practices.
Following a recommendation from the Nominating and Corporate Governance Committee, the Board appointed Chief Executive Officer Erik Lundgren as a Class II director, effective July 5, 2026. He will serve until the 2028 annual meeting of stockholders. Lundgren will receive no additional compensation for board service, has not joined any board committee, and aside from his existing employment agreement and CEO compensation, the filing notes no related-party transactions requiring disclosure.
IMMUNIC, INC. director Jon Congleton received a grant of stock options covering 50,740 shares of common stock. The options have an exercise price of $10.90 per share and were conditionally approved by the Board on March 27, 2026, subject to stockholder approval of an amendment to the 2019 Omnibus Equity Incentive Plan, which was obtained at the 2026 Annual Meeting on June 29, 2026. The options vest in 36 equal monthly installments from March 27, 2026, and expire on March 27, 2036, leaving Congleton with 50,740 options following this grant.
IMMUNIC, INC. director Simona Skerjanec received a grant of stock options covering 25,370 shares of common stock. The options carry an exercise price of $10.90 per share and are fully vested as of March 27, 2026. The grant was conditionally approved by the board on March 27, 2026 and became effective after stockholders approved an amendment to the company’s 2019 Omnibus Equity Incentive Plan at the 2026 Annual Meeting held on June 29, 2026. Following this grant, Skerjanec holds 25,370 stock options directly.